4530 久光製薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2025/02	3Q	111,253	13,220	11.9%	16,471	14.8%	13,660	12.3%	185.02	8.2%	7.7%	-1.1%	12.8%
2024/02	3Q	102,827	12,270	11.9%	16,661	16.2%	12,110	11.8%	156.64	11.9%	44.3%	28.1%	27.2%
2023/02	3Q	91,881	8,506	9.3%	13,003	14.2%	9,522	10.4%	119.46	6.0%	22.0%	50.1%	53.1%
2022/02	3Q	86,663	6,973	8.0%	8,665	10.0%	6,218	7.2%	76.14	7.2%	-14.2%	9.3%	8.7%
2021/02	3Q	80,822	8,123	10.1%	7,928	9.8%	5,722	7.1%	70.04	-18.4%	-55.9%	-60.2%	-62.9%
2020/02	3Q	99,078	18,417	18.6%	19,917	20.1%	15,420	15.6%	187.36	-3.4%	15.5%	14.4%	15.7%
2019/02	3Q	102,574	15,941	15.5%	17,412	17.0%	13,329	13.0%	159.35	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2025/02	3Q	8,426	950	11.3%	-190	-2.3%	1,550	18.4%	28.38	-23.0%	-74.8%	赤転	-40.1%
2024/02	3Q	10,946	3,764	34.4%	3,658	33.4%	2,588	23.6%	37.18	109.8%	145.5%	-15.7%	-21.7%
2023/02	3Q	5,218	1,533	29.4%	4,338	83.1%	3,304	63.3%	43.32	-10.7%	黒転	488.6%	566.1%
2022/02	3Q	5,841	-1,150	-19.7%	737	12.6%	496	8.5%	6.10	黒転	赤縮	黒転	黒転
2021/02	3Q	-18,256	-10,294	56.4%	-11,989	65.7%	-9,698	53.1%	-117.32	赤拡	赤転	赤転	赤転
2020/02	3Q	-3,496	2,476	-70.8%	2,505	-71.7%	2,091	-59.8%	28.01	赤転	-84.5%	-85.6%	-84.3%
2019/02	3Q	102,574	15,941	15.5%	17,412	17.0%	13,329	13.0%	159.35	-	-	-	-